Laboratoires Pierre Fabre
Eau Thermale Avène
Laboratoires Pierre Fabre is the world's second-largest dermo-cosmetics laboratory and the undisputed leader in mineral-based skincare, founded in 1962 in Castres, France. With annual revenue of €3.2 billion, the group operates 5 major manufacturing sites in France and 43 subsidiaries across 5 continents, employing 10,000 people. Its flagship brand Avène leverages the unique mineral composition of thermal spring water from the Cévennes Mountains, combining pharmaceutical-grade R&D with natural mineral actives to dominate the global sensitive skin market. The company achieved a historic milestone in 2025, surpassing €3 billion in revenue three years ahead of schedule.
Strengths: Absolute control over mineral water source purity with 90% of products manufactured in France ensuring unparalleled quality consistency; unique foundation-owned governance structure (86.3% held by Pierre Fabre Foundation) shields the company from short-term market pressures and enables reinvestment of all profits into R&D (€250 million in 2025, +14% YoY); exceptional penetration in Asian markets with 12.7% sales growth in China alone in 2025; AFNOR-certified "Exemplary" CSR rating reflecting deep commitment to sustainability and global health access.
Weaknesses: Heavy concentration of manufacturing in France creates significant exposure to European regulatory and labor cost inflation; high dependency on a single geographical mineral source (Avène spring) represents a supply chain single point of failure; limited presence in the mass-market segment compared to competitors with broader price-tier coverage.Read MoreShow Less
Strengths: Absolute control over mineral water source purity with 90% of products manufactured in France ensuring unparalleled quality consistency; unique foundation-owned governance structure (86.3% held by Pierre Fabre Foundation) shields the company from short-term market pressures and enables reinvestment of all profits into R&D (€250 million in 2025, +14% YoY); exceptional penetration in Asian markets with 12.7% sales growth in China alone in 2025; AFNOR-certified "Exemplary" CSR rating reflecting deep commitment to sustainability and global health access.
Weaknesses: Heavy concentration of manufacturing in France creates significant exposure to European regulatory and labor cost inflation; high dependency on a single geographical mineral source (Avène spring) represents a supply chain single point of failure; limited presence in the mass-market segment compared to competitors with broader price-tier coverage.
In the press
All coverage →5 latest headlines21- Pierre Fabre Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease - PR Newswirewww.prnewswire.com2026-10-14
- Atara, Pierre Fabre take third shot at FDA approval of Ebvallo - BioWorld Newswww.bioworld.com2026-10-01
- Laboratoires Pierre Fabre Appoints Nicolas Zombré CEO - Beauty Packagingwww.beautypackaging.com2026-08-26
- Laboratoires Pierre Fabre Appoints Nicolas Zombré CEO of U.S. Dermocosmetics Business, Signaling Next Phase of Growth - Yahoo Financefinance.yahoo.com2026-08-25
- Laboratoires Pierre Fabre Appoints Nicolas Zombré as CEO of US Dermocosmetics Business - Cosmetics & Toiletrieswww.cosmeticsandtoiletries.com2026-08-25
• Avène Eau Thermale mineral spring water sprays and sensitive skin treatment ranges using unique 2:1 calcium-to-magnesium ratio mineral composition
• Klorane botanical-mineral hybrid hair and scalp care products utilizing plant-based active ingredients combined with mineral clays
• Ducray pharmaceutical-grade dermatological treatments for severe skin conditions including psoriasis and eczema
• René Furterer essential oil and mineral clay scalp treatments and hair care systems
• A-Derma oat-based dermo-cosmetic products for fragile and atopic skin
• Elancyl slimming and anti-cellulite body care leveraging mineral salts and plant extracts
• Global oncology support skincare line developed specifically for chemotherapy and radiotherapy patients
Quick Facts
Headquarters
Founded
Employees
Revenue
Factories
Presence
Listing
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.3 T
- Allergan Aesthetics· $506 B
- Procter & Gamble· $393 B
- Merck Animal Health· $330 B
- BHP Group· $173 B
- China Shenhua Energy Company Limited· $169 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website , Pierre Fabre Key Figures | Pierre Fabre 2025 Results | Fortune Business Insights: Mineral Cosmetics Market | Fortune Business Insights: Ceramic Cookware Market
